Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Sun Pharma among 4 stocks to hit 52-week highs & rally up to 25% in a month
The Sensex ended higher as select BSE 200 stocks touched fresh 52-week highs. FSN E-Commerce Ventures, Titan, Sun Pharmaceutical Industries and Lenskart Solutions led the momentum.
Sun Pharmaceutical Industries Ltd spurts 0.07%, up for five straight sessions
Sun Pharmaceutical Industries Ltd is quoting at Rs 1914.2, up 0.07% on the day as on 12:44 IST on the NSE. The stock is up 14.45% in last one year as compared to a 4.11% fall in NIFTY and a 16.43% fall in the Nifty Pharma.
Indian pharma, CDMOs set to gain from US cancer drug supply crunch: Bernstein
Zydus Lifesciences, Lupin and Sun Pharmaceutical Industries could benefit from a US oncology drug supply crunch and India's emerging GLP-1 market opportunity, according to Nandan Kulkarni, Senior Analyst-India Healthcare at Bernstein. He believes Indian biopharma companies are strengthening their role in global healthcare supply chains.
Five Stocks To Buy: Adani Power, Ola Electric, IRCTC And More | June 24, 2026
Top picks for Wednesday, June 24 include Adani Power, Sun Pharmaceutical Industries, Ola Electric, IRCTC, and GRP Limited.
Sun Pharmaceutical Industries Ltd spurts 1.19%, rises for fifth straight session
Sun Pharmaceutical Industries Ltd is quoting at Rs 1885, up 1.19% on the day as on 12:44 IST on the NSE. The stock is up 13.44% in last one year as compared to a 4.38% drop in NIFTY and a 15.7% drop in the Nifty Pharma.
Sun Pharma to acquire 100% stake in Innovcare Lifesciences for Rs 271 crore
Sun Pharmaceutical Industries said that it has entered into an agreement for acquiring 100% outstanding shares of Innovcare Lifesciences for a total consideration of Rs 271.2 crore.
Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transaction
India's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash deal. This strategic move aims to bolster Sun Pharma's product offerings. Innovcare, which markets pharmaceutical drugs, nutraceuticals, and cosmeceuticals, reported steady revenue growth in recent fiscal years. The transaction, expected to conclude by July 2026, is a significant step for Sun Pharma's expansion.
Sun Pharmaceutical among 5 Nifty stocks showing bullish RSI upswing
Five Nifty50 stocks featured in the RSI Trending Up scan on June 17 after showing improving momentum. The RSI moved above the 50 mark from lower levels, signalling strengthening price action, improving sentiment and potential short-term buying opportunities for traders tracking bullish technical setups.
Sun Pharmaceutical Industries fixes record date for final dividend
Record date is 07 July 2026
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MF
A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund acquiring the stake. The transaction comes amid strong earnings growth, healthy margins and sustained momentum in the company’s pharmaceutical business.
SBI in $1 billion funding for Sun Pharma’s US deal
State Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move marks a significant step for government-run banks in financing corporate takeovers. SBI will join other global lenders in this substantial deal. The funding underscores the growing ambition of Indian companies to expand globally.
Sun Pharmaceutical Industries Ltd drops for fifth straight session
Sun Pharmaceutical Industries Ltd is quoting at Rs 1774.1, down 0.81% on the day as on 13:19 IST on the NSE. The stock jumped 5.41% in last one year as compared to a 5.65% slide in NIFTY and a 11.71% spurt in the Nifty Pharma index.